# Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT

Study · id `cardio:ct-nct01880216` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01880216](<https://clinicaltrials.gov/study/NCT01880216>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01880216

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 312 participants.

## Technical summary

Registry record NCT01880216. Randomized; single masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2015-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 312 participants (enrolled count; ClinicalTrials.gov record NCT01880216, source copy `cardio:ctgov-nct01880216-2016-02-04`, retrieved 2026-10-31)
- Start date: 2013-06 (registry gives no type) (ClinicalTrials.gov record NCT01880216, source copy `cardio:ctgov-nct01880216-2016-02-04`, retrieved 2026-10-31)
- Primary completion: 2015-01 (actual) (ClinicalTrials.gov record NCT01880216, source copy `cardio:ctgov-nct01880216-2016-02-04`, retrieved 2026-10-31)
- Completion: 2015-05 (actual) (ClinicalTrials.gov record NCT01880216, source copy `cardio:ctgov-nct01880216-2016-02-04`, retrieved 2026-10-31)
- Countries: Georgia; Russia (ClinicalTrials.gov record NCT01880216, source copy `cardio:ctgov-nct01880216-2016-02-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01880216-2016-02-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
- Condition: Deep Vein Thrombosis
- Intervention (Drug): Bemiparin sodium
- Intervention (Drug): Enoxaparin sodium
- Lead sponsor: Berlin-Chemie AG Menarini Group
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial (`cardio:pubmed-29214507`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1ac5223620f11cef62028d9b1631ae93de3df7146fb703bbbb873a4129dc2f66
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
